文献速递神经头颈MR

颅底脊索瘤钆增强的预后意义

Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas.
PubMed 文献 · AJNR Am J Neuroradiol · 2018-06-14

回顾性分析22例经病理确诊的颅底脊索瘤患者,评估术前MRI增强及T2信号特征与肿瘤进展/复发的相关性。14例增强肿瘤中11例(78.6%)术后进展/复发,8例无增强肿瘤中零例进展/复发,增强与进展/复发显著相关(P < .001),控制治疗策略差异后仍显著(P < .001);增强后T1肿瘤/脑干信号比也与复发/进展相关(P = .02)。结论认为颅底脊索瘤增强是手术切除后肿瘤进展/复发的危险因素。

要点

  • 颅底脊索瘤增强者术后进展/复发11/14(78.6%),无增强者0/8,增强与进展/复发显著相关(P < .001)。
  • 控制治疗策略差异后,增强与进展/复发的相关性仍显著(P < .001)。
  • 增强后T1肿瘤/脑干信号比与复发/进展相关(P = .02),T2信号比与进展无显著关联(P = .12)。

核心结论

  • 颅底脊索瘤增强是手术切除后肿瘤进展/复发的危险因素。

研究设计与样本

  • 回顾性研究,纳入22例经病理确诊的颅底脊索瘤患者,记录手术切除程度、是否放疗及进展/复发时间,评估术前MRI增强有无及T2信号特征,计算T2、增强前T1和增强后T1自旋回波序列肿瘤/脑干信号强度比。

关键影像表现/征象

  • 增强肿瘤14例中11例(78.6%)术后进展/复发,无增强肿瘤8例中零例进展/复发;无进展者T2肿瘤/脑干信号比中位数2.27,进展者中位数1.78,该关联无统计学显著(P = .12)。

诊断标准与关键数值

  • 增强与肿瘤进展/复发显著相关(P < .001),控制治疗策略差异后仍显著(P < .001);增强后T1肿瘤/脑干信号比与复发/进展相关(P = .02)。

临床应用与阅片要点

  • 术前MRI评估颅底脊索瘤增强有无及增强后T1肿瘤/脑干信号比,可能有助于提示术后进展/复发风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Skull base chordomas often demonstrate variable MR imaging characteristics, and there has been limited prior research investigating the potential clinical relevance of this variability. The purpose of this retrospective study was to assess the prognostic implications of signal intensity on standard imaging techniques for the biologic behavior of skull base chordomas.

MATERIALS AND METHODS: Medical records were retrospectively reviewed for 22 patients with pathologically confirmed skull base chordomas. Clinical data were recorded, including the degree of surgical resection, the presence or absence of radiation therapy, and time to progression/recurrence of the tumor or time without progression/recurrence of the tumor following initial treatment. Pretreatment imaging was reviewed for the presence or absence of enhancement and the T2 signal characteristics. Tumor-to-brain stem signal intensity ratios on T2, precontrast T1, and postcontrast T1 spin-echo sequences were also calculated. Statistical analysis was then performed to assess correlations between imaging characteristics and tumor progression/recurrence.

RESULTS: Progression/recurrence of skull base chordomas was seen following surgical resection in 11 of 14 (78.6%) patients with enhancing tumors and in zero of 8 patients with nonenhancing tumors. There was a statistically significant correlation between skull base chordoma enhancement and subsequent tumor progression/recurrence (P < .001), which remained significant after controlling for differences in treatment strategy (P < .001). There was also a correlation between postcontrast T1 signal intensity (as measured by postcontrast T1 tumor-to-brain stem signal intensity ratios) and recurrence/progression (P = .02). While T2 signal intensity was higher in patients without tumor progression (median tumor-to-brain stem signal intensity ratios on T2 = 2.27) than in those with progression (median tumor-to-brain stem signal intensity ratios on T2 = 1.78), this association was not significant (P = .12).

CONCLUSIONS: Enhancement of skull base chordomas is a risk factor for tumor progression/recurrence following surgical resection.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Lin E, Scognamiglio T, Zhao Y, et al. Prognostic Implications of Gadolinium Enhancement of Skull Base Chordomas. AJNR Am J Neuroradiol. 2018. PMID: 29903925. doi:10.3174/ajnr.A5714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。